Vishwanath Reddy, MD
Internal Medicine · Anniston, ALNPI 1952375354
Payments from drug & device makers
Across 54 payments — averaging $18.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$221
- Novo Nordisk$154
- Exact Sciences$96
- Phathom Pharmaceuticals, Inc.$67
- AstraZeneca$58
- KCI USA, Inc.$55
- plus $338 from 16 others
What the payments were for
- Food & beverage$94996%
- Education$404%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 12 | $221 |
| Novo Nordisk | 9 | $154 |
| Exact Sciences | 5 | $96 |
| Phathom Pharmaceuticals, Inc. | 3 | $67 |
| AstraZeneca | 4 | $58 |
| KCI USA, Inc. | 3 | $55 |
| Paratek Pharmaceuticals, Inc. | 2 | $36 |
| Apria Healthcare LLC | 2 | $35 |
| E.r. Squibb & Sons, L.L.C. | 1 | $35 |
| Organogenesis Inc. | 1 | $25 |
| Solventum Corporation | 1 | $24 |
| Merck | 1 | $23 |
| Cumberland Pharmaceuticals, Inc. | 1 | $21 |
| GSK | 1 | $21 |
| Melinta Therapeutics, LLC | 1 | $18 |
| Astellas Pharma US Inc | 1 | $18 |
| Boehringer Ingelheim | 1 | $17 |
| Novartis | 1 | $15 |
| Lilly USA, LLC | 1 | $13 |
| Pfizer | 1 | $13 |
| Smith+Nephew | 1 | $12 |
| Johnson & Johnson | 1 | $12 |
How this compares
$989 in reported general payments places this provider in the 60th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 258 | $276,247 |
| MounjaroTirzepatide | 125 | $136,748 |
| EliquisApixaban | 158 | $124,072 |
| RybelsusSemaglutide | 61 | $106,995 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 66 | $81,888 |
| JardianceEmpagliflozin | 77 | $78,659 |
| Tresiba Flextouch U-200Insulin Degludec | 49 | $77,393 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 74 | $62,599 |
| JanuviaSitagliptin Phosphate | 47 | $60,918 |
| XareltoRivaroxaban | 43 | $37,531 |
| SynjardyEmpagliflozin/Metformin Hcl | 45 | $37,451 |
| LinzessLinaclotide | 48 | $30,953 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 33 | $28,073 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $27,710 |
| FarxigaDapagliflozin Propanediol | 40 | $23,442 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $154 | $383,242319 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance, Synjardy, Stiolto Respimat | $17 | $207,238204 claims |
| Lilly USA, LLCMounjaro, Trulicity | $13 | $155,802142 claims |
| PfizerEliquis | $13 | $124,072158 claims |
| MerckJanuvia, Janumet Xr | $23 | $80,52163 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $21 | $72,22387 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $58 | $51,51673 claims |
| Johnson & JohnsonXarelto | $12 | $37,53143 claims |
| Astellas Pharma US IncMyrbetriq | $18 | $13,77315 claims |
| NovartisEntresto | $15 | $10,31816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Anniston
- Almena FreeAnniston$12.7M
- Harry StuddardMobile$12.9M
- Hayes WilliamsVestavia$10.4M
- David DeatkineBirmingham$8M
- James SullivanBirmingham$6M
- Ramy TomaBirmingham$5.1M
- Barry McLeanHomewood$4M
- William KirbyBirmingham$2.3M
- Saadat AnsariHuntsville$2.1M
- Gregory FlippoTrussville$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.